Robert Wessman (born 4 October 1969) is an Icelandic pharmaceutical entrepreneur and executive known for founding and leading several major generics and biosimilars companies. He led the turnaround of Icelandic drugmaker Delta (later Actavis) into a global generics firm, then founded Alvogen in 2009 and Alvotech in 2013. Over his career he has built companies worth billions of dollars. Wessman was named “Best CEO in the Pharmaceuticals Industry” by European CEO in 2018. His work has been the subject of multiple Harvard Business School case studies, and he remains a leading figure in generics and biosimilars research and development.
Early Life and Education
Wessman was born and raised in Iceland. He grew up in the Reykjavík area (in Seltjarnarnes and later Mosfellsbær) and attended local schools. He earned a Bachelor of Business Administration from the University of Iceland in 1993. After graduation, he worked for Icelandic shipping firm Samskip for seven years. At Samskip he first served in finance and later became CEO of its German operations. This early career in logistics helped him learn international business before he returned to Iceland to work in pharmaceuticals.
Career
Delta and Actavis
In 1999 Wessman became CEO of Delta, a near-bankrupt Icelandic generic drug company. He merged Delta with another Icelandic firm (Pharmaco) and rebranded the combined business as Actavis in 2004. Under Wessman’s leadership Actavis grew rapidly: it acquired dozens of companies across Europe, the US and Asia, and expanded its product lineup to hundreds of drugs. By 2008 Actavis had become a multibillion-dollar pharmaceutical group with about 11,000 employees. Wessman stepped down as Actavis CEO in 2008 to pursue new ventures. (Actavis later sold its generic division to Teva in 2017.)
Alvogen and Related Ventures
In 2009 Wessman founded Alvogen, a pharmaceutical company focused on generics and biosimilars. He led Alvogen’s growth by buying an ailing U.S. generic maker and forming manufacturing and R&D teams in North America, Eastern Europe and Asia. By 2017 Alvogen was estimated to be worth about $4 billion. Under Wessman’s tenure Alvogen built a portfolio of hundreds of generic medicines sold worldwide.
Many of Alvogen’s early goals came from a famous 2009 investor pitch: Wessman sketched on a napkin how to use an old plant in New York (Norwich Pharmaceuticals) to enter the U.S. market. Despite the 2008 financial crisis (in which Wessman personally lost about $250 million), he convinced investors to renovate and use that site. He became executive chairman of the new Alvogen, initially taking a 30–40% ownership stake. The company’s rapid growth (50 new products in year one) was attributed to Wessman’s strategy and recruiting former colleagues.
In the 2010s Alvogen continued to expand. Wessman oversaw a series of acquisitions and product launches, especially in Central/Eastern Europe and Asia. Alvogen spun off two subsidiaries as independent firms: Lotus (Taiwan) and Adalvo (Malta) in 2021–22, with Wessman remaining as Chairman of each. He also founded a Swiss investment holding, Aztiq, to manage these assets. Alvogen itself achieved over $1 billion in annual revenue by 2017 before being sold to a private equity consortium.
Alvotech (Biosimilars)
In 2013 Wessman co-founded Alvotech, a pure-play biosimilars company headquartered in Reykjavik. Alvogen provided a $250 million capital investment to build Alvotech’s research and manufacturing facilities. Alvotech’s strategy has been to fully integrate its R&D and production under one roof and partner for marketing in various regions. Wessman chose Iceland for Alvotech’s plant, even though it was an unconventional location for a biopharma factory.
Under Wessman’s leadership Alvotech grew into a global biosimilar developer. In June 2022 Alvotech went public on the Nasdaq stock markets (dual-listing in New York and Iceland) through a SPAC merger. (Wessman served as Executive Chairman during this IPO.) The company then began selling its own biosimilar medicines. In 2024 its Reykjavik plant was FDA-certified, allowing it to launch Simlandi (a biosimilar to Humira) in the U.S. market. By 2025 Alvotech had several biosimilar drugs approved or awaiting approval in the U.S. and Europe. The company reported hundreds of millions in revenue in 2024 and continues to grow under Wessman’s vision of making high-cost biologic treatments more affordable.
Summary of Key Roles
- CEO of Delta/Actavis (1999–2008): Turned around Delta, created Actavis (now a major generics company).
- Founder & CEO of Alvogen (2009–2022): Built Alvogen into a multi-billion-dollar global generics firm.
- Founder & Executive Chairman of Alvotech (2013–present): Led development of biosimilars and oversaw its 2022 public listing.
- Chairman of Lotus (Taiwan) and Adalvo (Malta): Spun-off Alvogen subsidiaries (2021) with Wessman as Chairman.
- Other ventures: Through his wife’s Maison Wessman brand he launched a French vineyard and wine label.
Personal Life and Public Image
Wessman is private about his family, but public sources note that he and his wife have six children between them. His wife’s name is not publicly disclosed. He has spoken openly about overcoming dyslexia in his youth, saying the challenge gave him determination and focus. Wessman is also known as an avid cyclist (he was once a competitive racer) and as a vintner: he owns a vineyard in southwestern France and markets wines under Maison Wessman.
There is no public record of his height or net worth, and such personal details have not been disclosed. As of 2026 he is 56 years old (born 1969). He remains based in Iceland and frequently travels to oversee his global companies. Wessman maintains a low personal profile on social media; he is occasionally quoted in industry publications and participates in biotech conferences.
Public Recognition
Wessman’s business achievements have drawn attention in media and industry. He has been profiled by outlets like European CEO and World Finance, and is the subject of Harvard Business School case studies. In addition to being named “Best CEO” in 2018, he has received other awards in the pharmaceutical world (for example, industry honors at global generics conferences). His story – from an Icelandic childhood to leading a pharma empire – often illustrates entrepreneurship in the face of adversity.
Frequently Asked Questions
Who is Robert Wessman?
Robert (Róbert) Wessman is an Icelandic entrepreneur known for founding and running pharmaceutical companies. He built the generics firm Actavis (through mergers) and later founded Alvogen and Alvotech.
What companies did he found or lead?
He founded Alvogen (2009) and Alvotech (2013). He also led Actavis (originally CEO of Delta, 1999–2008), and has chaired its spin-offs Lotus and Adalvo. In summary, his companies include Actavis, Alvogen, Medis, Adalvo, Lotus, and Alvotech.
How old is Robert Wessman?
He was born on 4 October 1969, so he is currently 56 years old (as of 2026).
Where is he from and what is his education?
Wessman is Icelandic, born and raised near Reykjavík. He earned a BA in Business Administration from the University of Iceland in 1993.
Is Robert Wessman married, and does he have children?
Yes. Wessman is married (his wife’s name is not public) and together they have six children. Further personal details are kept private.
What awards or honors has he received?
He was named European CEO’s Best CEO in the Pharmaceuticals Industry in 2018. His business strategies have been recognized in multiple Harvard Business School case studies. Industry groups have honored him at biotech and generics conferences, for example presenting him with leadership awards (as seen in photos of Wessman receiving trophies).
Does Robert Wessman have a known net worth?
No reliable public data is available on Wessman’s net worth. He has famously seen his personal wealth fluctuate with company fortunes (losing about $250M in the 2008 crash), but official figures have not been released.
What is his height?
His height has never been publicly reported.
Conclusion
Robert Wessman is a significant figure in the global pharmaceutical industry. From his roots in Iceland to leading international generics and biosimilar companies, he has proven adept at building and scaling businesses. Readers interested in the pharmaceutical sector may follow news on Alvotech and Alvogen for the latest on Wessman’s work. For ongoing updates, check reputable business news outlets or the official company websites listed above.
Sources: Authoritative profiles and news reports on Robert Wessman (see citations).